SAN DIEGO, Dec. 8, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at the Deutsche Bank Biotech Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET / 10:35 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the Company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
CONTACT: Michael York, Senior Director, Investor Relations of Amylin
Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602
Web site: http://www.amylin.com/
